StockMarketWire.com - AI data analytics company Ixico said it had secured three new biopharma contracts and appointed Lammert Albers as chief business officer, effective immediately. The three new contracts included a start up agreement with a new client for a new multi-study programme in progressive supranuclear palsy (PSP), with an initial value of about £0.4m, over 12 months. It also included a £0.3m, three-year, expansion of an existing study to add a significant patient cohort in China and a £0.45m, two-year, new client contract to support a phase IV study for a US biotech client, exploring a new application for a marketed drug for mental health.

The company had been contracted to initiate work on a new PSP programme for a client, ahead of patient enrolment later in 2019. The first study in the programme had a value of approximately £0.4m and was expected to lead to a larger programme of work in early 2020, the company added.



At 9:09am: [LON:IXI] IXICO plc share price was +3p at 72.5p



Story provided by StockMarketWire.com